Drugs / h5G1.1-mAb
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00005571 | Apr 2000 → Dec 2001 | dermatomyositis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | h5G1.1-mAb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005571 ↗ |
| Route | Intravenous | “The drug or placebo will be given intravenously (through a thin tube inserted into a vein)” NCT00005571 ↗ |
| Target | C5 | “This is a randomized, third-party, placebo-controlled pilot study of h5G1.1-mAb, an antibody directed at the complement component C5” NCT00005571 ↗ |